I
n the heart, the sarcoplasmic reticulum (SR) acts needs to dissociate from troponin C to terminate cross-bridge cycling. Hence, the cytosolic Ca 2þ concentration has to be decreased to w100 nmol/l mainly via Ca 2þ reuptake into the SR through the cardiac sarcoplasmic reticulum Ca 2þ pump 2a (SERCA2a) at the cost of ATP consumption (1) . Although SERCA2a activity is crucial for normal diastolic function, dysregulation of SERCA2a represents a central molecular defect in heart failure.
In a simplified model (Figure 1 ), systolic trans- Science author instructions page. Hasenfuss and Lehnart
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Negative Adrenergic Feedback Specific to Phospholamban A P R I L 2 0 1 7 : 1 8 1 -3 was proposed for therapeutic targeting in heart failure (11) . Recently, miR-765, which is increased in human failing hearts, was shown to suppress I-1 expression, which may depress cardiac function through enhanced PP1 activity (12) . In this regard, the new finding that PP2Ce regulates PLN differs considerably from PP1 because: 1) PLN seems to be a specific substrate of PP2Ce in the myocardium; and 2) PP2Ce was up-regulated following ISO stimulation, and therefore, may constitute an inhibitory feedback loop. These aspects not only add important new insights about PLN regulation in general, because increased PP2Ce expression was associated with human heart failure and cardiac-specific PP2Ce overexpression increased ischemia/reperfusion injury (3), but may contribute to new opportunities for PLN-targeted, SERCA2a-modulatory therapeutic approaches.
